ANI Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 7, 2025, at 8:30 a.m. ET

About this update from Ani Pharmaceuticals, Inc.

PRINCETON, N.J. , Oct. 24, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company will release its third quarter 2025 financial results on Friday, November 7, 2025 , prior to the market open. Nikhil Lalwani , President and Chief Executive Officer, Stephen P. Carey , Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz , Head of Rare Disease will host a conference call to discuss the results as follows: Date Friday, November 7, 2025 Time 8:30 a.m. ET Toll free ( U.S. ) 800-267-6316 Conference ID 5120265 Webcast (live and replay) www.anipharmaceuticals.com , under the “Investors” section A replay of the conference call will be available within two hours of the call’s completion and will remain accessible for two weeks by dialing 800-839-2391 and entering access code 5120265. About ANI ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S. -based manufacturing; and its Brands business. For more information, visit www.anipharmaceuticals.com . Investor Relations: Courtney Mogerley , Argot Partners T: 646-368-8014E: [email protected] Source: ANI Pharmaceuticals, Inc.

View stock analysis, news, and events for Ani Pharmaceuticals, Inc.